|
CURRENT RESEARCH INTERESTS
Development of novel therapeutic strategies and implementation of
targeted biologic agents into treatment paradigms of peripheral T-cell
lymphomas and cutaneous T-cell lymphomas
CURRENT CLINICAL INTERESTS
Non-Hodgkin and Hodgkin lymphomas; acute lymphoblastic leukemia
RESEARCH DESCRIPTION
Active Clinical trials:
UW-6640 Phase II Prospective Study of Pralatrexate and Gemcitabine for
patients with relapsed PTCL.
UW-08020
Phase II Prospective Study of Romidepsin (Depsipeptide) for patients
with relapsed PTCL.
UW-6914
Phase II Study of Vorinostat (SAHA) for patients with untreated CTCL.
UW-08032
Phase II Study of SGN-35 (anti-CD30 mAb with immunotoxin) for patients
with relapsed ALCL, ALK-negative.
UW-08004
Phase II Study of Forodesine (BCX1777) in patients with relapsed CTCL.
UW-6774
Phase II Study of Pralatrexate in patients with relapsed CTCL.
UW-6959
Phase II Study of Pegylated Asparaginase with intensive chemotherapy
for patients with newly diagnosed acute lymphoblastic
leukemia.
SELECTED
PUBLICATIONS
Via CS, Nguyen P, Shustov AR,
Drappa J, Elkon KB. A major role of the Fas pathway in Acute
Graft-versus-Host Disease. J. Immunol. 157:5387-5393,
1996.
Shustov AR, Nguyen P,
Finkelman FD, Elkon KB and Via CS. Differential expression of
Fas and Fas ligands in acute and chronic GVHD: upregulation of Fas and
Fas ligand requires CD8+T cell activation and INF-gamma
production. J. Immunol. 161:2848-2855, 1998.
Shustov AR, Luzina IG,
Nguyen P, Papadimitriou JC,Handwerger BS, Elkon KB and Via CS.
Role of perforin in controlling B cell hyperactivity and humoral
autoimmunity. J. Clin. Invest. 106(6):R39-R47, 2000.
Via CS, Shustov AR, Rus
V, Lang T, Nguyen P, Finkelman FD. In vivo neutralization of
tumor necrosis factor alpha promotes humoral autoimmunity by
preventing the induction cytotoxic T lymphocytes. J. Immunol.
167:6821-6826, 2001.
Shustov AR and Savage
KJ. Does high-dose therapy and autologous hematopoietic stem
cell transplantation have a role in the primary treatment of
peripheral T-cell lymphomas? ASH Evidence-based Review 2008,
American Society of Hematology, Education Program Book. Pages
39-41.
Shustov AR. T-cell
lymphoma-one name with a dozen faces. Leuke. Lymphoma
49(11):2033-2034,2008.
Puliaeva I, Puliaev R, Shustov
AR, Hass M, and Via Cs. Fas expression on antigen-specific
T-cell responses but not for T-cell-dependent B cell responses. J.
Immunol. 181(9):5912-29, 2008.
Furman RR, Forero-Torres A, Shustov
A, Drachman JG. A phase I study of Dacetuzumab (SGN-40), a
humanized anti-CD-40 monoclonal antibody) in patients with chronic
lymphocytic leukemia. Clin. Cancer Res. (in review).
Shustov
AR, Rus
V, Nguyen P and Via CS. Murine
Graft-versus-Host Disease: relevance to human lupus immunopathogenesis
and therapy. In: Lupus:
Cellular and Molecular Pathogenesis.
G.T. Tsokos & G.M.Kammer (Eds), pp
140-151, 2000.
Shustov
AR and
Via CS. Transplantation
and autoimmunity. In: Molecular
Pathology of Autoimmunity. A.N.
Theophilopoulos et al. (Eds), pp 1055-1065, 2001.
Shustov AR and Appelbaum
FR. T-cell acute lymphoblastic leukemia. In: Adult
Acute Lymphocytic Leukemia: Biology and Treatment. Humana
Press (to be published in 2010).
|
